Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to
subjects with chronic hepatic impairment and in matched healthy subjects.